度洛西汀用于无中枢敏化的单次双侧全膝关节置换术患者的镇痛效果:一项前瞻性、双盲、随机、安慰剂对照试验
该前瞻性双盲随机安慰剂对照试验纳入106例在脊髓麻醉下接受单次双侧全膝关节置换术且无中枢敏化的患者,比较术前2天至术后28天每日20 mg度洛西汀与安慰剂的镇痛效果。度洛西汀组在术后48小时、1周和2周的静息及活动视觉模拟评分、患者满意度和额外非甾体抗炎药消耗量均优于安慰剂组,两组安全性相当;上述结局从4周随访起变得可比。
要点
- 无中枢敏化患者单次双侧全膝关节置换术后每日20 mg度洛西汀可改善术后2周内的静息及活动疼痛评分。
- 度洛西汀组患者满意度更高(8.44 ± 1.68 vs 7.17 ± 1.04;P < .001),额外非甾体抗炎药消耗更少。
- 两组安全性相当;疼痛结局从4周随访起变得可比。
核心结论
- 在无中枢敏化的患者中,每日20 mg度洛西汀可安全、成功地管理双侧全膝关节置换术后持续性疼痛,改善患者满意度及急性术后阶段的镇痛药物消耗。
研究设计与样本
- 前瞻性、双盲、随机、安慰剂对照试验,纳入106例在脊髓麻醉下接受单次双侧全膝关节置换术的患者。
- 两组匹配,一组给予20 mg度洛西汀,另一组给予外观和重量相似的安慰剂,给药时间从术前2天至术后28天。
- 随访时间点为48小时、1周、2周、4周和3个月。
- 疼痛采用静息视觉模拟评分和活动视觉模拟评分(mVAS)测量;次要指标包括额外非甾体抗炎药消耗量、患者满意度和安全性。
主要发现
- 度洛西汀组静息视觉模拟评分在术后48小时(6.38 ± 1.32 vs 7.02 ± 0.99;P = .017)、1周(4.76 ± 1.24 vs 5.89 ± 1.06;P < .001)和2周(3.34 ± 1.19 vs 4.26 ± 1.02;P < .001)随访时优于安慰剂组。
- 度洛西汀组活动视觉模拟评分在术后48小时(7.23 ± 1.12 vs 8.21 ± 0.69;P < .001)、1周(5.83 ± 1.11 vs 6.82 ± 0.92;P < .001)和2周(3.70 ± 0.89 vs 4.60 ± 1.03;P < .001)随访时显著高于安慰剂组。
- 两组静息和活动视觉模拟评分从4周随访起变得可比。
- 度洛西汀组患者满意度(8.44 ± 1.68 vs 7.17 ± 1.04;P < .001)和额外非甾体抗炎药消耗量(2,770 ± 533.05 vs 3,566.04 ± 464.54;P < .001)均优于安慰剂组,安全性相当。
临床怎么用
- 作者认为,对于无中枢敏化的患者,每日20 mg度洛西汀可安全、成功地管理双侧全膝关节置换术后持续性疼痛,并改善急性术后阶段的患者满意度和镇痛药物消耗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pain control and patient satisfaction after total knee arthroplasty (TKA) have room for improvement. While studies have reported better analgesic outcomes with antidepressants like duloxetine in patients who do not have central sensitivity (CS), we undertook this trial to determine the short and midterm analgesic role of low-dose duloxetine in patients who do not have CS. METHODS: This prospective, double-blinded, randomized, placebo-controlled trial was conducted in 106 patients undergoing single-setting, bilateral TKA under spinal anesthesia. There were 2 matched groups, with one given 20 mg of duloxetine and the other given a placebo (similar in appearance and weight) from preoperative day 2 to postoperative day 28. Follow-ups were scheduled at 48-hours, 1-week, 2-weeks, 4-weeks, and 3-months. Pain was measured using a visual analogue scale at rest and visual analogue scale at mobilization (mVAS). Secondary measures included additional non-steroidal anti-inflammatory drug consumption, patient satisfaction, and safety profile. RESULTS: The visual analogue scale at rest in the duloxetine group was better in the first 48 hours (6.38 ± 1.32 versus 7.02 ± 0.99; P = .017), 1-week (4.76 ± 1.24 versus 5.89 ± 1.06; P < .001), and 2-weeks (3.34 ± 1.19 versus 4.26 ± 1.02; P < .001) follow-up. The mVAS remained significantly higher in the duloxetine group in the first 48 hours (7.23 ± 1.12 versus 8.21 ± 0.69; P < .001), 1-week (5.83 ± 1.11 versus 6.82 ± 0.92; P < .001), and 2 weeks (3.70 ± 0.89 versus 4.60 ± 1.03; P < .001) follow-up. Both outcomes became comparable from 4-week follow-up onward. Patient satisfaction (8.44 ± 1.68 versus 7.17 ± 1.04; P < .001) and additional non-steroidal anti-inflammatory drug consumption (2,770 ± 533.05 versus 3,566.04 ± 464.54; P < .001) were better in the duloxetine group, with a comparable safety profile. CONCLUSIONS: In patients who did not have CS, persistent pain after bilateral TKA can be managed safely and successfully by a daily dose of 20 mg Duloxetine, improving patient satisfaction and analgesic consumption in the acute postoperative phase.
引用
- Rajani AM, Mittal ARS, Kulkarni VU, et al. Duloxetine as an Analgesic in Patients Who Do Not Have Central Sensitivity Undergoing Single-Setting, Bilateral Total Knee Arthroplasty: A Prospective, Double-Blinded, Randomized, Placebo-Controlled Trial. J Arthroplasty. 2024. PMID: 38355065. doi:10.1016/j.arth.2024.02.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。